
WuXi Buys Pfizer China Plant
China’s WuXI Biologics has agreed to buy Pfizer’s biologics manufacturing facilities in Hangzhou for an undisclosed price. The transaction is expected to close in the first half of 2021. The Shanghai-based company said the acquisition will immediately boost its capacities for commercial drug substance (DS) and drug product (DP) capacities to address surging manufacturing demand.









































